What is Cepharanthine?

 

The national innovation patent recently authorized a novel crown treatment medicine discovered by Chinese experts. According to the patent specification, 10um (micromol / L) stephanine suppresses coronavirus reproduction by 15393 times. According to Professor Tongyigang, the patent's inventor and Dean of the School of Life Science and Technology at Beijing University of Chemical Technology, the drug's ability to inhibit novel coronaviruses ranks high among all novel coronavirus inhibitors discovered by humans based on current research data.

Cepharanthine, a white blood cell proliferation medication, can boost bone marrow tissue proliferation and increase white blood cells. To treat leukopenia. It can cause a rise in leukocytes in the peripheral blood. Animal studies have revealed that it can considerably decrease mitomycin-induced leukopenia while not inhibiting mitomycin's anticancer impact. Its method is to enhance bone marrow tissue proliferation, resulting in an increase in leukocytes. It is used to treat agranulocytosis produced by tumor treatment and radiotherapy, as well as leukopenia from other causes.

What is Cepharanthine?

 

Stephanine, also known as stephanine base, has the chemical formula C37H38N5O6 and the English name Cepharanthine.

 

Stephanine is not a brand-new medication. Saburo Fujiwara, a Japanese pharmacist, was the first to extract it from Stephania tenuifolia in 1934. Stephanine has been utilized in clinical settings for many years. It is a prescription medication. It was first used to treat tuberculosis, and the result was widespread. However, it was discovered that many patients' leukocytes increased significantly during treatment, so later researchers attempted to use stephanine in the treatment of leukopenia, particularly in the anti-tumor process (such as radiotherapy and chemotherapy), which is the main clinical use of stephanine at the moment.

It can boost leukocytes and enhance bone marrow tissue proliferation. It is most commonly used to treat neutropenia produced by tumor chemotherapy and radiotherapy, as well as leukopenia caused by other factors. According to the chemical encyclopedia, powdered root powder is currently the primary raw material used in the production of stephanine. However, it is fully chemically manufactured.

Anti-Xinguan medicines were screened out in January 2020, following the outbreak of COVID-19. Professor Tong Yigang, Dean of the School of Life Science and Technology at Beijing University of Chemical Technology, tested thousands of medications in the lab and eventually found several effective pharmaceuticals, the most effective of which is stephanine. Following that, institutional studies in the United States and Japan discovered that stephanine is superior to other medications in the treatment of Xinguan, which is the most effective therapy now available.